Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

We assessed the utility of droplet digital PCR (ddPCR) to evaluate the potential of using circulating tumour DNA (ctDNA) as a post therapy monitoring tool in melanoma by comparing it to serum LDH levels and RECIST scores. ddPCR was shown to be reliable in distinguishing mutant from wild type alleles with no false positives. Subsequently, we quantified ctDNA (V600EBRAF,V600KBRAF or Q61HNRAS) in 6 stage IV melanoma patients across several time points during their treatment course. All tested patients had detectable ctDNA, which exhibited dynamic changes corresponding to the changes in their disease status. The ctDNA levels fell upon treatment response and rose with detectable disease progression. In our group of patients, ctDNA was more consistent and informative than LDH as a blood-based biomarker. In addition, BRAF mutant ctDNA as detected by ddPCR could be used diagnostically where the tumour block was unavailable. In conclusion, this study demonstrates the applicability of using ddPCR to detect and quantify ctDNA in the plasma of melanoma patients.

[1]  F. Lozupone,et al.  Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.

[2]  D. Rigel,et al.  The Evolution of Melanoma Diagnosis: 25 Years Beyond the ABCDs , 2010, CA: a cancer journal for clinicians.

[3]  C. Gedye,et al.  The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel , 2013, Pigment cell & melanoma research.

[4]  P. J. Pretorius,et al.  Circulating DNA , 2008, Annals of the New York Academy of Sciences.

[5]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[7]  W. Westra,et al.  Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis , 2007, The American Journal of dermatopathology.

[8]  H. Müller,et al.  Circulating Nucleic Acids in Plasma or Serum (CNAPS) as Prognostic and Predictive Markers in Patients with Solid Neoplasias , 2005, Disease markers.

[9]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[10]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[11]  J. Wolchok,et al.  Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. , 2014, Cancer treatment reviews.

[12]  Drew M Pardoll,et al.  Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade , 2014, Journal of Immunotherapy for Cancer.

[13]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[14]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[15]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[16]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[17]  K. Griewank.  Biomarkers in melanoma , 2016, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[18]  R. Zárate,et al.  Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .

[19]  D. Schadendorf,et al.  Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Min Yu,et al.  Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. , 2014, The Journal of molecular diagnostics : JMD.

[21]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.

[22]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.